2017 Top Stories in Oncology: Disappointments and Glimpses of Hope

1. Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954-1963.
2. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol. 2005;7:369(abstr 342).
3. van den Bent MJ, Eoli M, Sepúlveda JM, et al. Depatux-M (ABT-414) alone or Depatux-M plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group. Annual Meeting, Society of Neuro-Oncology, San Francisco, November 2017.
4. Reardon D for the Checkmate 143 investigators. World Federation of Neuro-Oncology Societies Quadrennial Meeting. Zurich, May 2017, NCT02017717
5. Michael Weller, Nicholas Butowski, David D Tran, et al, for the ACT IV trial Investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373-1385.
6. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA. 2015;314:2535-2543.

7. Stupp R, Taillibert S, Kanner A, et al. Final results of the EF-14 phase 3 randomized clinical trial comparing tumor-treating fields plus maintenance temozolomide to maintenance temozolomide alone for newly diagnosed glioblastoma. JAMA. 2017 Dec 19.

8. van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390(10103):1645-1653.
9. Blumenthal DT, Gorlia T, Gilbert MR, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol. 2017;19(8):1119-1126.
10. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049-1060.
11. Peters S, Camidge DR, Shaw AT, et al; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829-838.
12. Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Ann Oncol. 2017;28(suppl 5):Abstr LBA2_PR.

Disclosure statements are available on the authors' profiles: